Yahoo Web Search

  • FirefoxTry Yahoo Search on Firefox »
    1. Sort by

    1. Research and Markets has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2015" report to their offering.

    2. HACKENSACK, N.J. and PETACH TIKVAH, Israel, Jan. 11, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, ...

    3. HACKENSACK, N.J. and PETACH TIKVAH, Israel, Jan. 11, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has entered into a collaborative agreement with...

    4. NEW YORK, Jan. 11, 2016 /PRNewswire/ -- A new ALS treatment utilizing a stem cell infusion protocol performed at Hadassah Medical Organization (HMO) and developed by the US/Israeli biotech company BrainStorm Cell Therapeutics (BCLI), has significantly slowed the progression of Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's Disease), announced Ellen Hershkin, National President of...

    5. NEW YORK, Jan. 11, 2016 /PRNewswire/ -- A new ALS treatment utilizing a stem cell infusion protocol performed at Hadassah Medical Organization (HMO) and developed by the US/Israeli biotech company BrainStorm Cell Therapeutics (NASDAQ: BCLI), has significantly slowed the progression...

    6. HACKENSACK, N.J. and PETACH TIKVAH, Israel, Jan. 11, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced the publication of a paper in the January 2016 edition of JAMA...

    7. HACKENSACK, N.J. and PETACH TIKVAH, Israel, Jan. 11, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced the publication of a paper in the January 2016 edition of JAMA Neurology discussing the outcome of the first in man Phase 1/2 study and Phase 2 dose escalation study with NurOwn® in ALS ...

    8. DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/g22znf/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis Prostate Cancer, complete with comparative analysis at ...

    9. Translational Regenerative Medicine: Market Prospects 2016-2026

      PR Newswire via Yahoo! FinanceFeb 08 06:00 AM

      LONDON, February 8, 2016 /PRNewswire/ -- Can Promising Therapies in Stem Cells, Tissue Engineering and Gene Therapy Change the Way We Treat Rare and Chronic Diseases? What can be expected from the Translational ...

    10. Huntington's Disease Pipeline Review, H2 2015 - Research and Markets

      Business Wire via Yahoo! FinanceJan 21 09:24 AM

      Research and Markets has announced the addition of the "Huntington's Disease - Pipeline Review, H2 2015" report to their offering.

    1. 12330 results